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ABSTRACT
Interactions between pairs of membrane-bound receptors can enhance tumour 
development with implications for targeted therapies for cancer. Here we demonstrate 
clear heterotypic interaction between CD74 and CD44, which might act in synergy 
and hence contribute to breast cancer progression. CD74, a type II transmembrane 
glycoprotein, is a chaperone for MHC class II biosynthesis and a receptor for the 
MIF. CD44 is the receptor for hyaluronic acid and is a Type I transmembrane protein. 
Interactions between CD74, MIF and the intra-cytoplasmic domain of CD44 result in 
activation of ERK1/2 pathway, leading to increased cell proliferation and decreased 
apoptosis. The level of CD44 in the breast tumor cell lines CAMA-1, MDA-MB-231, 
MDA-MB-435 and the immortalized normal luminal cell line 226LDM was higher than 
that of CD74. It was also observed that CD74 and CD44 exhibit significant variation 
in expression levels across the cells. CD74 and CD44 were observed to accumulate 
in cytoplasmic compartments, suggesting they associate with each other to facilitate 
tumour growth and metastasis. Use of a novel and validated colocalisation and image 
processing approach, coupled with co-immunoprecipitation, confirmed that CD74 
and CD44 physically interact, suggesting a possible role in breast tumour growth. 
This is the first time that CD74 and CD44 colocalization has been quantified in breast 
cancer cells using a non-invasive and validated bioimaging procedure. Measuring 
the co-expression levels of CD74 and CD44 could potentially be used as a ‘biomarker 
signature’ to monitor different stages of breast cancer.
INTRODUCTION
Simultaneous expression of the cluster of 
differentiation (CD) 74 and CD44 has been identified in 
several types of cancer and is believed to play a role in 
tumour development [1–3]. CD74, is a nonpolymorphic 
type II integral membrane glycoprotein expressed by 
antigen-presenting cells [4]. CD44, a type I transmembrane 
glycoprotein, and member of the cartilage link protein 
family is expressed in most cell types and is a receptor 
for hyaluron and osteopontin [5]. CD44 is involved in 
cell-to-cell and cell-extracellular matrix interactions, 
cell adhesion and migration. In a previous study, we 
showed that adhesion of tumour cells on the reconstituted 
membrane matrix Matrigel increases when CD74 and 
CD44 are overexpressed [6]. This was accompanied by 
increased expression of membrane-bound and soluble 
proteins involved in cell adhesion and cancer metastasis. 
In breast cancer cells, the lipid-modified glycoprotein, 
WNT5A, inhibits metastasis and alters the splicing of 
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CD44 [7]. Recently, it has been shown that CD74 and 
CD44 promote actin polymerization via RHOA-mediated 
CFL1 phosphorylation; it is thought that this interaction 
contributes to tumour metastasis [8].
CD74 protein exists in a number of isoforms which 
are post-translationally glycosylated [1]. The best known 
function of CD74 is as a chaperone involved in stabilizing 
nascent human leucocyte antigen (HLA)-DR class II αβ-
heterodimers [9–11]. By means of two motifs in its cytosolic 
Nʹ-terminus, Ii directs class II nonamers toward endosomal 
compartments in which peptide loading occurs. Lastly, 
aminoacid (aa) 81-104 of Ii, termed CLIP (class II-associated 
invariant chain peptide), which is bound in the class II 
peptide binding groove, prevents loading of endoplasmic 
reticulum (ER)-resident peptides onto HLA class II. The 
expression of MHC class II in tumors, including colorectal 
and breast carcinomas, has been previously observed [12]. 
HLA-DR proteins in breast epithelium, which normally 
lacks MHC II expression, may be induced by cytokines or 
hormones [13]. Coordinate expression of HLA-DR, CD74 
and HLA-DM by tumour cells is thought to be an indicator 
of improved prognosis in breast carcinoma. Several groups 
have suggested that the expression of HLA molecules 
improves immunogenicity of tumour cells and induce an 
anti-tumour T-cell response [14–16].
CD74 is also the ligand for the innate cytokine 
macrophage migration inhibitory factor (MIF), which 
binds with high affinity to the extracellular domain of 
cell surface CD74 [17, 18]. It also interacts with amyloid 
precursor protein and suppresses amyloid-β protein 
synthesis [19]. In immune cells, MIF binding to CD74 
induces a signaling cascade regulating cell proliferation 
and survival [20]. CD74 lacks intracellular signalling 
domains, with MIF-induced extracellular signal-regulated 
kinase (ERK) signalling reliant upon CD44 [21, 22]. To 
enable interaction with CD44, CD74 is modified by the 
addition of chondroitin sulfate, permitting formation of a 
molecular complex between MIF, CD74 and CD44 [23, 
24].
CD44 has been the subject of research interest 
because of its potential role in breast cancer. CD44 
activates and inhibits oncogenic signalling in response 
to extracellular signals [25, 26]. Expression of CD44 is 
upregulated in premalignant lesions and is associated with 
particular cancer types, including prostate cancer, head and 
neck squamous-cell carcinoma, central nervous system 
malignancies, respiratory track malignancies, melanoma 
and breast cancer [27–30]. The CD44 gene undergoes 
extensive alternative splicing of multiple variable exons 
that are positioned in a cassette in the middle of the gene 
[31]. Present in most cell types, CD44s, the standard splice 
isoform, comprises exons 1-5 and 16-20; CD44v isoforms 
are splice variants containing variable exons. It is possible 
that expression of alternative CD44 exons is associated 
with tumour progression. However, expression of CD44 
in human breast tumors is correlated with both favourable 
and unfavourable clinical outcomes [25, 32].
Previously, we have demonstrated that high 
expression of signal transducer and activator of 
transcription 1 (STAT1) and CD74 is associated with 
triple-negative breast cancer [6]. The present study sought 
to characterize the cell-surface and total protein expression 
of CD74 and CD44 in three human breast cancer cell 
lines types (CAMA-1, MDA-MB-231, MDA-MB-435) 
and in normal luminal 226LDM cells. Heterotypic 
interaction between CD74 and CD44 is for the first 
time demonstrated at a quantitative level using a novel 
colocalization and image processing approach coupled 
with co-immunoprecipitation (Co-IP) techniques.
RESULTS
Identification and quantification of CD74 and 
CD44
The cell surface expression of CD74 and CD44 was 
appraised in CAMA-1, MDA-MB-231, MDA-MB-435, 
Raji and cervical cancer HeLa cells. Monocytes, Raji 
cells and HeLa cells were used as a positive control, since 
CD74 in monocytes and CD44 in Raji cells and HeLa cells 
are expressed in high amounts. Non-permeabilized cells 
were stained with By2 (anti-CD74) and 156-3C11 (anti-
CD44) antibodies, followed by addition of RAM-FITC, 
as a secondary antibody. CD74 and CD44 were clearly 
detected in the plasma membrane of CAMA-1, MDA-
MB-231 and MDA-MB-435 cells (Figure 1).
Laser scanning confocal microscopy, using different 
wavelengths, was used to visualize intracellular expression 
of CD74 and CD44 molecules. The CAMA-1, MDA-
MB-231 and MDA-MB-435 cell lines all expressed CD74 
and CD44 in intracellular compartments (Figure 2).
Immunoblot analysis of CD74 and CD44 
proteins
In order to ascertain that the receptors detected by 
the antibodies corresponded to CD74 and CD44, protein 
expression in CAMA-1, MDA-MB-231, MDA-MB-435, 
Raji and HeLa cells was studied by Western blot analysis 
using By2 (anti-CD74), 156-3C11 (anti-CD44) and 
Poly6221 (anti β-Actin). β-actin was used as a loading 
control. CD74, CD44 and β-actin have molecular weights 
of 33-41 kDa, 80-90 kDa and 42 kDa, respectively (Figure 
3). All cell lines expressed two CD74 isoforms, the p35 
and p41 isoforms (Figure 3A; right panel). CAMA-1 cells 
expressed two isoforms of CD44, with molecular weight 
of 80 kDa and 90 kDa (Figure 3A; left panel). Figure 3B 
shows the expression percentages of CD74 and CD44, 
with expression data normalized to the β-Actin reference.
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Expression of CD74 and CD44 in normal breast 
cells
We examined the expression of CD74 and CD44 in 
immortalized normal luminal 226LDM cells. Cell-surface 
and intracellular expression of both proteins was assessed 
by flow cytometry (Figure 4A). Total expression level of 
CD74 and CD44 was detected by Western blot analysis 
with α-tubulin used as a loading control (Figure 4B). 
Confocal laser-scanning microscopy was utilized to study 
the intracellular staining of CD74 and CD44 in 226LDM 
cells (Figure 4C). The results show that 226LDM cells do 
not express detectable levels of CD74. However, the cells 
express CD44 in intracellular compartments, with weak 
cell surface expression.
Colocalization analysis of CD74 and CD44
To investigate whether CD74 and CD44 co-
localize, both molecules were visualized separately 
at different wavelengths, appearing as green and red 
spots, respectively, in the image (Figure 5A-5C). The 
immunofluorescence-stained cells were imaged at 
single cell level. Data were analysed using the Pearson 
correlation coefficient (PCC). Figure 5D illustrates 
the colocalization of CD74 and CD44 in each cell 
line compared to the negative control, comprising 
colocalization of DAPI against FITC. For more accuracy, 
3D images were acquired in stack in the z-direction and 
segmented by NIS elements to calculate the exact degree 
of colocalization of CD74 and CD44 molecules against 
the total volume in each of the images (Figure 5A, 5B and 
5C). The three breast cancer cell lines exhibited yellow/
orange fluorescence in single cell images, signifying 
closely associated CD74 and CD44 receptors (Figure 
5A-5C, panel at the far right). PCC values ranged from 
0.784 to 0.858, reflecting distributions of probes that are 
correlated with one another, indicative of colocalization.
Interaction of CD74 and CD44
To further demonstrate interaction between CD74 
and CD44, Co-IP was carried out. An interaction occurred 
between CD74 and CD44 in cell lysates from CAMA-1, 
Figure 1: Cell surface expression of CD74 (upper panel, (A) and CD44 (lower panel, (B) on CAMA-1, MDA-MB-231, 
MDA-MB-435, Raji and HeLa cells.  All cells were cultured in the appropriate media and were acquired by flow cytometry using By2 
(anti-CD74) and 156-3C11 (anti-CD44). Empty histograms represent the aforementioned cell lines labeled with anti-CD74 and anti-CD44 
antibody. Black-filled histograms show the isotypes serving as negative controls. Cells were labelled using FITC-labelled secondary anti-
mouse antibody. Expression levels were analyzed by flow cytometry (Aria cell sorter) and FlowJo 8.8.6 software was used to analyze the 
data. Mean fluorescence intensity (MFI) values were measured based on geometric means. Mouse IgG was used as a negative control. Data 
are representative of three independent experiments.
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MDA-MB-231 and MDA-MB-435 cells (Figure 6B). It 
was also revealed that, in CAMA-1 cells, CD74 interacts 
with both CD44s and CD44v isoforms. MDA-MB-231 
and MDA-435 cells expressed only CD44s, which 
interacted with CD74. To test whether CD44s and CD44v 
interact with all isoforms of CD74 we performed Co-IP 
experiments with lysates of CAMA-1, MDA-MB-231 and 
MDA-435 cells, using either anti-CD74 or anti-CD44. The 
results obtained show that CD44s and CD44v bind p41 
CD74 alone (Figure 6C).
DISCUSSION
We report the physical association of CD74 and 
CD44 and consider their likely function in breast cancer 
cells. Figure 7 summarize known interactions associated 
with CD74 and CD44 and the present results. Current 
data suggest that co-expression of CD74 and CD44 can 
play a significant role in the pathogenesis of various solid 
tumours [22, 33, 34]. No direct quantification has yet been 
conducted on the association of the two molecules. MIF-
Figure 2: Confocal laser scanning microscopy images of intracellular staining of CD74 and CD44 in CAMA-1, MDA-
MB-231 and MDA-MB-435 cells.  The cells were cultured in LabTek 8-well chambers at a density of 6 x 103 cells per well overnight. 
CD74 was labelled with Alexa Fluor 488 (green) and CD44 with Alexa Fluor 555 (red). 4′, 6-diamidino-2-phenylindole was used for 
nuclear staining (blue). Fluorochromes were acquired separately to evaluate the expression of CD74 and CD44 using the image-analysis 
software platform Fiji. Photomicrographs are representative of three independent experiments. Scale bar 10 μm.
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Figure 3: Western blot analysis of CD74, CD44 and β-actin expression in the CAMA-1, MDA-MB-231, MDA-MB-435 
and Raji cells. (A) Primary monoclonal antibodies Poly6221 (anti-β-actin as loading control), By2 (anti-CD74) and 156-3C11 (anti-
CD44) were used. β-actin was detected at a molecular weight of 42 kDa; CD74 isoforms were detected at molecular weights 35 and 41 kDa, 
whereas CD44 isoforms were detected at molecular weights 80 and 90 kDa. (B) CD74 and CD44 levels are normalized against β-actin. To 
account for the difference in protein loading during the experiment, the percentage of expression was calculated after the intensity of each 
band was adjusted according to its respective β-actin band intensity using the Image Studio Lite software (LI-COR Biosciences). Figures 
depict representative samples from triplicate experiments displayed as composites of multiple Western blots.
Figure 4: The expression of CD74 and CD44 receptors in immortalized normal breast luminal cells (226LDM). (A) 
Cell-surface and intracellular expression of CD74 and CD44 was acquired by flow cytometry using By2 (anti-CD74) and 156-3C11 
(anti-CD44). Black-filled histograms represent the 226LDM cells stained with indicated antibody. Empty histograms show the isotype as 
negative controls. (B) Total protein of CD74 and CD44 was detected by Western blotting, and α-tubulin was used as a loading control. (C) 
Confocal images of CD74 and CD44 in 226LDM cells stained intracellularly: CD74 was labelled with Alexa Fluor 488 (green) and CD44 
with Alexa Fluor 555 (red). Figures depict representative samples from duplicate experiments. Scale bar 10 μm.
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Figure 5: Colocalization of CD74 and CD44 intracellularly of (A) CAMA-1, (B) MDA-MB-231 and (C) MDA-MB-435 
cells, determined by confocal microscopy analysis. Yellow/orange fluorescence reveals the potential colocalization of two antigens. 
3D images were acquired in stack, with z-direction step size 0.14 μm using NIS element. Single-plane of z-stack is shown in three directions 
as xy, yz and zx. (D) Graphical representation of colocalization analysis based on Pearson’s correlation coefficient PCC of each cell. 
Data represent three different experiments. Figures depict representative samples from triplicate experiments. All data were statistically 
significant (P-values < 0.05).
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induced ERK1 and ERK2 kinase phosphorylation requires 
CD74 and co-expression of full-length CD44 [21]. MIF 
also interacts with the p53 tumor suppressor, inhibiting 
p53-responsive gene activation and apoptosis [35, 36]. To 
facilitate signaling, MIF binds to the extracellular domain 
of macrophage and B cell CD74 [17, 34]. However, CD44 
is required for MIF signal transduction, due to lack of 
direct signalling via the cell-surface domain of CD74 
[37]. When CD74 forms a complex with CD44, CD74 is 
modified by the addition of chondroitin sulfate, which is 
essential for the MIF-induced signaling cascade [37, 38]. 
It has been suggested that the CD74-MIF-CD44 complex 
initiates a pro-survival signal leading to reduced apoptosis 
and increased cell proliferation [21, 39].
Because CD74 and CD44 are both involved in 
MIF-mediated signalling, CD74 is considered a potential 
therapeutic target in cancer [24]. Therefore it is relevant 
to quantify the association of CD74 and CD44 in cancer 
cells. Meyer-Siegler et al. Showed that CD44 binds to p35 
CD74 in bladder cancer cells, the isoform suggested to be 
involved in antigen presentation [33, 40]. Meyer-Siegler et 
al. Found that prostate cancer loses expression of CD44s 
and over-expresses almost entirely variant forms, which 
arise from alternate splicing of exons 7-10 [22]. This 
indicated potential involvement of CD44v in MIF-CD74-
mediated signal transduction in prostate cancer. However, 
human benign prostate hyperplasia epithelial cells (BPH-
1) and LNCaP prostate cancer cells do not express CD74 
on the cell surface. For this reason, both cell lines do not 
interact with CD44. LNCaP cells, however, have been 
demonstrated to interact with MIF [22].
We show that CD74 and CD44 molecules are 
detectable by flow cytometry in CAMA-1, MDA-MB-231 
and MDA-MB-435 breast cancer cells. Intracellular 
expression of CD74 and CD44 was detected by confocal 
microscopy. It was found that the level of expression 
of surface CD44 was significantly higher than that of 
CD74. High levels of CD74 expression might render 
tumors less immunogenic by blocking the MHC class 
II peptide-binding cleft, preventing binding of antigenic 
peptides for presentation to CD4+ lymphocytes [1, 41]. 
Indeed, several studies have shown that the level of CD74 
expression is proportionality associated with tumor grade 
[41]. Surface CD74 is a prerequisite for the internalization 
of HLA-DR:Ii complexes, which are targeted to early 
endosomes [9]. However, changes in CD74 surface 
expression do not necessarily correlate with the level of 
this internalization activity. It has been shown that CD44 
expression is associated with a high rate of cell division 
and proliferation status [28].
Western blotting revealed that CAMA-1, MDA-
MB-231 and MDA-MB-435 cells express two isoforms 
of CD74, p35 and p41. CAMA-1 cells were observed 
to express CD44s and one CD44 variant isoform, at 
molecular weights of 80 and 90 kDa, respectively. In 
contrast to our data, Verjans et al. found that MDA-
Figure 6: Co-immunoprecipitation (Co-IP) to study the interaction of CD74 and CD44 in CAMA-1, MDA-MB-231 
and MDA-MB-435 cell lines. (A, B) IP was subjected to pull down either CD74 or CD44. The blots were probed with either mouse 
anti-CD74 or anti-CD44 antibodies. The antibody (Ab) heavy and light chain bands are indicated so that Ab heavy and light chain fragments 
can be observed at approximately 55 and 25 kDa, respectively. (C, D) Co-IP was applied to study the interaction of CD74/CD44 and CD44/
CD74. The Co-IP of CD74/CD44 confirmed that all CD44 isoforms, including CD44s and CD44, interact with CD74. However, Co-IP 
of CD44/CD74 confirmed that only p41 of CD74 interacts with CD44. Figures depict representative samples from duplicate experiments 
displayed as composites of multiple co-immunoprecipitation.
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MB-231 and MDA-MB-468 cells express only one 
isoform of CD74 [34]. Similarly, Metodieva et al. Found 
that MDA-MB-435 express one CD74 isoform [42]. 
Two small CD74 isoforms, p33 and p35, are likely to be 
involved in regulating class II MHC antigen presentation 
while the p41 isoform may play an important role in T cell 
selection in the thymus [43, 44].
In terms of its function, the human-specific p35 
CD74 isoform is the most enigmatic CD74 isoform. Use 
of an alternative translation initiation site in p35 adds 
R-X-R, an ER retention motif. It is thought that the R-X-R 
motif is blocked when MHC II binds CD74, permitting 
egress of MHC II/CD74 complexes from the ER. Mouse 
transgenic studies by Genève et al. Utilizing mice that lack 
Figure 7: The interaction between CD74 and CD44 on the surface of cells. CD74 is a single-chain type II integral membrane 
protein monomer; its expression is linked to the biosynthesis of HLA-DR, as shown in the left panel. CD74 associates with HLA-DR 
and is recycled into clathrin vesicles for peptide editing by HLA-DM. Cell-surface CD74 functions as a ligand for the cytokine MIF, 
as shown on the right panel. CD74 loaded with MIF interacts with CD44, a cell surface type I glycoprotein expressed on most cell 
types including cancer cells. Upon interaction CD44 activates the proto-oncogene tyrosine-protein kinase Src signal transduction pathway 
leading to NF-κB post-transcriptional regulation of genes. The role of CD74 and CD44 interaction in the turnover of these molecules is 
currently unknown. Acronyms: CD74, cluster of differentiation 74; CD74-ICD, cluster of differentiation 74 cytosolic domain; CD44, 
cluster of differentiation 44; HLA-DR, human leukocyte antigen-DR; HLA-DM, human leukocyte antigen-DM; MIIC, MHC class II 
compartment; MIF, macrophage migration inhibitory factor; MAPK/ERK, mitogen-activated protein kinase/extracellular signal-regulated 
kinase signalling cascade; NF-κB, nuclear factor κB; NF-κB/RelA, RelA subunit of nuclear factor κB; PI3K, phosphatidylinositol 3-kinase; 
TAFII105, TBP-associated factor.
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endogenous CD74, indicate that p35 retains the antigen 
presenting functions of other CD74 isoforms in T-cell-
positive selection and peripheral maintenance [40]. This 
suggested that p33 and p35, together, facilitate antigen 
presentation, and that this process does not require the co-
expression of any other CD74 isoform [1, 40]. If so, the 
p35 isoform could substitute for other CD74 isoforms if 
they were absent.
Western blot analysis showed that CAMA-1 cells 
co-express CD44s and CD44v. Jung et al. Showed that 
some breast cancer cell lines, such as MDA-MB-468 
and SUM149, express several isoforms of CD44 [45]. 
It is possible that CD44 expression in breast cancer is 
associated with highly aggressive breast tumour subtypes 
or highly invasive breast cancer cells [46].
We have studied immortalized normal breast 
luminal cells (226LDM). Confocal microscopic images 
showed that these cells did not express CD74, but did 
express intracellular and cell surface CD44. The absence 
of CD74 in 226LDM cells was anticipated, since CD74 
has, so far, only been detected in antigen-presenting cells, 
including B cells, monocytes, macrophages, dendritic cells 
and Langerhans cells, and in inflammatory cells, including 
those detected in cancers [47]. The presence of CD44 in 
normal breast cells is expected, since CD44 has a wide 
range of functions in normal tissues. Our results showed 
very low CD44 surface expression in 226LDM cells with 
higher intracellular expression.
Confocal microscopy analysis revealed that 
CD44 and CD74 are highly colocalized on endosomal 
membranes in CAMA-1, MDA-MB-231 and MDA-
MB-435 cells. The colocalization results obtained by 
correlation coefficient and total segmented volume 
indicated that CAMA-1 cells possess the greatest number 
of colocalized CD74 and CD44 molecules, followed by 
MDA-MB-435 and MDA-MB-231 cells. However, the 
degree of colocalisation in all three tumour cell groups 
was comparable.
colocalization between CD74 and CD44 may 
suggest that both are involved in signalling pathways 
along with MIF. CD44 has been found to form an active 
signalling complex with ErbB2 [48]. It also can anchor 
matrix metalloprotease-7 to the membrane, resulting in 
activation of ErbB4 [49].
One mechanism by which CD44 reaches 
intracellular sites is processing of its transmembrane 
form by consecutive cleavages by metalloproteases and 
c-secretase to generate a soluble extracellular domain and 
an intracellular domain. The latter is translocated to the 
nucleus where it activates transcription of genes involved 
in cell migration and attachment [50, 51]. Pályi-Krekk et 
al. Observed that hyaluronan oligosaccharide, epidermal 
growth factor and heregulin induce CD44 shedding, which 
was accompanied by endocytosis of full length CD44 
and intramembrane cleavage, with accumulation of its 
intracellular domain in the cytosol [52].
In B cells, CD74 is internalized into endocytic 
compartments. Within them, intramembrane cleavage 
releases its cytosolic intracellular domain, CD74-ICD, 
which then enters the nucleus, activates NF-κB p65/
RelA, and controls the differentiation of B cells through 
the TAFII105 coactivator [4, 53]. Studying HT-29 colon 
adenocarcinoma cells, Moldenhauer et al. Showed that 
CD74/Ii utilizes two internalization motifs to internalize 
HLA-DR molecules, to deliver HLA-DR:Ii to early 
endosomes [9].
Upregulation and colocalization of CD74 and CD44 
was observed in a preliminary pilot study using Grade 
III triple negative cancer cells, matched for size and 
nodal status (Al Ssadh Hussain, unpublished data). The 
present study has clearly demonstrated the occurrence of 
quantifiable colocalization between CD74 and CD44 in the 
plasma membrane of the breast cancer-derived cell lines 
CAMA-1, MDA-MB-231 and MDA-MB-435, suggesting 
interaction of these two molecules in breast cancer cells. 
We also found that CD44 in MDA-MB-435, CAMA-1 
and MDA-MB-231 cells displayed higher expression than 
CD74. The level of expression of cell surface CD74 was 
higher in MDA-MB-435 cells compared to CAMA-1 and 
MDA-MB-231 cells. Co-IP results confirmed that CD44 
interacts only with p41, the most abundant isoform of 
CD74.
The procedure used herein for identifying receptor 
pair associations can be applied to studying protein-
protein relationships in other cancers and could be used 
to assemble antibodies to monitor cancer progression. 
Although about 10-20% of breast cancers are triple 
negative, it would be of interest to study CD74 and CD44 
in a cohort of breast cancer cells tested negative for 
estrogen receptors, progesterone receptor, and HER2. In 
summary, measuring the co-expression levels of CD74 and 
CD44 could potentially be used as a ‘biomarker signature’ 
for examining different stages of breast cancer.
MATERIALS AND METHODS
Cell lines and cell culture
Three human mammary gland cell lines were used, 
CAMA- 1, MDA-MB-231 and MDA-MB-435, all derived 
from malignant pleural effusion. The CAMA-1 and MDA-
MB-435 cell lines were maintained in RPMI 1640 medium 
(LONZA-Belgium), supplemented with 10% (v/v) fetal 
calf serum (FCS; Imperial Laboratories, Andover, UK). In 
line with numerous studies, we used the MDA-MB-435 
cell line as a model for breast cancer, but acknowledge 
recent concerns that it might be derived from the M14 
cell line MDA-MB-435. The MDA-MB-231 cell line 
was maintained in D-MEM (high glucose), supplemented 
with 10% FCS. 226LDM immortalized normal breast 
luminal cells (kindly provided by Elena Klenova, School 
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of Biological Sciences, University of Essex), were used as 
positive control cells. Raji cells (human negroid Burkitt’s 
lymphoma) and HeLa cells (human cervical cancer), 
expressing high levels of CD74 and CD44, respectively, 
served as additional positive controls. The 226LDM cell 
line was maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM)/F-12, supplemented with 10% FCS, 5 
mg/ml gentamicine, 5 μg/m insulin, l ng/ml hydrocortine, 
20 ng/ml epidermal growth factor and 20 ng/ml cholera 
toxin. Raji and HeLa cells were cultured in RPMI 1640 
(LONZA-Belgium) containing 10% FCS and cultured in 
a humidified atmosphere of 5% CO2 at 37 °C. All media 
used for this study were purchased from PAA Laboratories 
GmbH (Pasching, Austria).
Reagents
The monoclonal primary antibodies mouse anti-
human CD74 (clone: By2) and mouse anti-human 
α-tubulin (clone: TU-02) were purchased from Santa Cruz 
Biotechnology, USA. Mouse antibody CD44 (clone: 156-
3c11) was purchased from Cell Signaling Technology, 
USA. Rabbit anti-human β-actin (clone: poly 6221) was 
purchased from BioLegend, UK. The secondary antibody 
used for flow cytometry was a goat anti-mouse antibody 
conjugated with the fluorophore FITC (clone: poly4053) 
and was purchased from Bio-legend, UK. The secondary 
antibody used for Western blotting was either goat anti-
mouse (IRDye 800CW) or goat anti-rabbit (IRDye 680 
LT), purchased from LI-COR Biosciences. Finally, 
Alexa 488 (green) and Alexa 555 (red) antibodies were 
purchased from Life Technologies, UK.
Flow cytometry analysis
Cell lines were lifted with Accutase (Sigma-Aldrich) 
and 1 x 106 cells were used per sample. Monoclonal 
antibodies By2 (anti-CD74) and 156-3c11 (anti-CD44) 
were employed in indirect immunofluorescence staining. 
Cells were preincubated with saturating concentrations 
of primary antibody, followed by washing and labeling 
with FITC-conjugated goat anti-mouse IgG (Bio-legend). 
For cell-surface staining, cells were fixed with 4% 
formaldehyde solution, and washed with 1X phosphate-
buffered saline (PBS). The cells were then blocked with 
blocking buffer (PBS/0.1% BSA, bovine serum albumin) 
and washed in PBS. Primary and secondary antibodies 
were diluted with 0.1% BSA in PBS. Cells were sorted on 
a BD FACSAria and analyzed by FlowJo 8.8.6.
Western blotting and immunodetection
Cells were lysed with CelLytic reagent (Sigma-
Aldrich) and total protein concentration was determined 
by Bradford assay. The total cell lysate was separated 
on a 12% SDS-PAGE gel. A total of 40 μg protein was 
loaded per well, and, after electrophoresis, protein 
was transferred to a polyvinylidene fluoride (PVDF) 
membrane (Immobilon-FL, Merck Millipore, Merck 
KGaA, Darmstadt, Germany). Membranes were blocked 
with 5% skimmed milk in PBS-Tween-20 (Sigma) for 1 h 
at room temperature and incubated in anti-CD74 (clone: 
By2) at a concentration of 1:200, and anti-CD44 (clone: 
156-3C11) at a concentration of 1:1000. As a control, an 
alpha subunit-specific tubulin mouse monoclonal antibody 
was used to probe the cell extracts at a concentration of 
1:200, followed by washing in PBS-Tween-20 for 30 min. 
The membranes were then incubated with IRDye 800CW 
donkey anti-mouse IgG (LI-COR Biosciences, Lincoln, 
NE, USA) at a concentration of 1:1000 for 1 h followed 
by washing in PBS-T for 30 min. Signals were detected 
using the ODYSSEY Infrared Imaging System (LI-COR 
Biosciences). Fermentas PageRuler™ Plus Prestained 
Protein Ladder (Thermo Fisher Scientific, Waltham, MA, 
USA) was used in order to estimate the molecular weight 
of the respective protein bands. To evaluate the differences 
in protein loading during the experiment, the percentage 
of expression was calculated after the intensity of each 
band was adjusted according to its respective β-actin 
band intensity using Image Studio Lite software (LI-COR 
Biosciences).
Immunofluorescence
In preparation for confocal immunofluorescence 
microscopy for studying colocalization between CD74 
and CD44 intracellularly, CAMA-1, MDA-MB-231 and 
MDA-MB-435 cells were cultured in LabTek 8-well 
chambers (Thermo Fisher Scientific) at a density of 6 x 103 
cells per well for two days. Following this they were 
seeded. The cells were fixed with 4% paraformaldehyde 
for 20 min on ice. For immunofluorescence staining, all 
procedures were carried out at ambient temperature. Cells 
were permeabilized with 0.1% Triton X-100 and then 
blocked with 2% (w/v) BSA prepared in 1X PBS for 1 h 
at room temperature. For single staining of each antigen, 
cells were incubated with anti-CD74 (clone: By2) at a 
concentration of 1:500, and anti-CD44 (clone: 156-3C11) 
at a concentration of 1:400 for 1 h, followed by three 
washes with PBS. Secondary antibody, anti-mouse IgG 
conjugated with Alexa Fluor® 488 or Alexa Fluor® 555 
(Invitrogen, Carlsbad, CA, USA), was used at a dilution 
of 0.25 μg/100ml for 1 h. For double staining, cells were 
blocked again with 2% BSA and the staining process was 
repeated for each desired pair. Cells were incubated with 
a primary antibody followed by a secondary antibody. 
CD74 was labeled with FITC Alexa Fluor 488 (green) 
and CD44 was labeled with Alexa Flour 555 (red). 
Colocalization, i.e. the overlap of CD74 with CD44, 
was assessed by merging green and red channels and the 
Pearson’s correlation coefficient was used to analyse the 
degree of colocalization. The scale lay between -1 and 1, 
where 1 stands for colocalization, -1 stands for negative 
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colocalization and 0 stands for no colocalization. 4’, 
6-diamidino-2-phenylindole di-hydrochloride (DAPI) 
counter stain (Vector Laboratories, Burlingame, CA, 
USA) was used at a 1:250 dilution. Cells were thoroughly 
washed with PBS, the chambers removed, and the slide 
was mounted with anti-fade mounting medium (Vector 
Shield) covered with a cover slip (Chance proper LTD, 
West Midlands, England) and sealed with rubber cement 
(Fixogum Rubber Cement, Marabu, Germany).
Quantitative colocalization analysis of confocal 
fluorescence microscopy images
To investigate whether CD74 and CD44 co localize, 
a high-precision single-cell bioimaging protocol was 
employed, previously developed by our research group 
[54]. The Pearson correlation coefficient of was used 
for quantitative analysis of colocalization [54, 55]. PCC 
provides a statistic able to measure the overall association 
of two probes in an image. It also indirectly measures 
quantity, i.e. the fraction of one protein that colocalizes 
with another protein. A Nikon A1Si confocal microscope 
(Nikon Instruments Inc.) with a plan-apochromatic VC1.4 
N.A. 60x magnifying oil-immersion objective was used 
for image acquisition. Images were acquired in three 
channels, using one-way sequential line scans. DAPI was 
excited at 398.7 nm with laser power 1.6 arbitrary units, 
and its emission was collected at 450 nm with a PMT gain 
of 86. Alexa Fluor 488 was excited at 488 nm with laser 
power 5.8; its emission was collected at 525 nm with a 
PMT gain of 117. Alexa Fluor 555 was excited at 560.5 
nm with laser power 3.7, and its emission was collected 
at 595 nm with a PMT gain of 98. The scan speed was ¼ 
frames/s (galvano scanner). The pinhole size was 35.76 
μm, approximating 1.2 times the Airy disk size of the 1.4-
NA objective at 525 nm. Scanner zoom was centered on 
the optical axis and set to a lateral magnification of 60 
nm/pixel. Axial step size was 105 nm, with 80-100 image 
planes per z-stack.
Image processing
NIS-Elements software (version 3.21.03, build 705; 
Nikon Instruments Inc.) was used for image processing. 
CD74 (green) and CD44 (red) channels were segmented 
using regional maxima detection tools followed by manual 
threshold. The generated binary areas were visually 
inspected; the overlap of the green and red channels, 
which were generated by the overlay tool, resulted in a 
new layer (yellow) that represents the intersection of 
CD74 and CD44. Finally, automated volume measurement 
was carried out for CD74 and CD44, and their intersection 
was measured by a volume measurement tool [54, 56].
Immunoprecipitation and  
co-immunoprecipitation
Cells were lysed with the RIPA Lysis Buffer System 
(Santa Cruz Biotechnology, USA) and total protein 
concentration was determined by Bradford assay. 1 mg/
ml of each sample was incubated overnight with 4 μg of 
anti-CD74 (clone: By2), at 4 °C. Following that, 40 μl 
of protein A/G PLUS-agarose (Santa Cruz Biotechnology, 
USA) was added. To promote immunoglobulin binding, 
this solution was kept overnight on a rotator at 4 °C. The 
samples were spun down for 30 s and the supernatant 
was discarded. Beads were then washed twice using PBS 
and the samples were boiled at 100 °C after adding 50 
μl of SDS-PAGE sample loading buffer containing di-
thiothreitol. Then 20 μl of each sample was loaded in 
each well of the gel and was left for 1 h and 30 min at 
120 V. After electrophoresis, protein was transferred to 
a PVDF membrane. Membranes were blocked with 5% 
skimmed milk in PBS-Tween-20 (Sigma) for 1 h at room 
temperature and incubated in either anti-CD74 (clone: 
By2) at a concentration of 1:200, or anti-CD44 (clone: 
156-3C11) at a concentration of 1:1000, and followed 
by washing in PBS-T for 30 min. The membranes were 
then incubated with secondary antibody (IRDye 800CW 
donkey anti-mouse IgG; LI-COR Biosciences, Lincoln, 
NE, USA) at a concentration of 1:1000 for 1 h, followed 
by washing in PBS-T for 30 min. Signals were detected 
using the ODYSSEY Infrared Imaging System (LI-
CORBiosciences).
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